Launch
Website- Bupa Platinum consultant
- Fee assured
- Verified account
- Open Referral network
Offers
- Face-to-face consultations
- Video and telephone consultations
About me
Prof Lee is a Professor of Medical Oncology at University College London (UCL), and a Consultant Medical Oncologist at UCL Hospitals (UCLH). He graduated from St. Mary’s Hospital Medical School in London, trained in internal medicine training at the London teaching hospitals of St Mary's, St Bartholomew’s and King’s College Hospitals, before completing his medical oncology fellowship training at Guy’s and Christie Hospitals. He specialises in the treatment of lung cancer and HIV-related cancers.
Prof Lee is an international recognised authority on lung cancer treatment and research. He is chief, co-chief or senior Investigator for several National Cancer Research Institute (NCRI) lung cancer studies, and his trials have led to changes in treatment paradigms for lung cancer patients. His work has been recognised at major international conferences with many invited presidential, plenary and oral lectures including at World Lung Cancer Conference, ASCO and ESMO. He has published and contributed to several practice-changing papers for both lung and other types of cancer, many as first or senior author in high-impact journals including NEJM, Nature, Lancet Oncology and JCO
Areas of interest
Lung cancer; Mesothelioma; HIV cancer
Medical secretaries
- Maureen Bucak
- Harley Street at University College Hospital 5th Floor U C H Macmillan Cancer Centre Huntley Street London WC1E 6AG
- 07545 207469
- 020 3447 1739
- uclh.lee.privatehcapa@nhs.net
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0005
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-56 days - (1-5)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (1-5)
-
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (1-5)